CA2445294A1 - Bisarylimidazolyl fatty acid amide hydrolase inhibitors - Google Patents
Bisarylimidazolyl fatty acid amide hydrolase inhibitors Download PDFInfo
- Publication number
- CA2445294A1 CA2445294A1 CA002445294A CA2445294A CA2445294A1 CA 2445294 A1 CA2445294 A1 CA 2445294A1 CA 002445294 A CA002445294 A CA 002445294A CA 2445294 A CA2445294 A CA 2445294A CA 2445294 A1 CA2445294 A1 CA 2445294A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- imidazol
- biphenyl
- carbamic acid
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003940 fatty acid amidase inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 116
- 208000002193 Pain Diseases 0.000 claims abstract description 26
- 230000036407 pain Effects 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 4
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 4
- 206010061218 Inflammation Diseases 0.000 claims abstract description 4
- 230000004054 inflammatory process Effects 0.000 claims abstract description 4
- 206010001513 AIDS related complex Diseases 0.000 claims abstract description 3
- 208000030814 Eating disease Diseases 0.000 claims abstract description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract description 3
- 206010020772 Hypertension Diseases 0.000 claims abstract description 3
- 206010028813 Nausea Diseases 0.000 claims abstract description 3
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 3
- 208000029808 Psychomotor disease Diseases 0.000 claims abstract description 3
- 235000014632 disordered eating Nutrition 0.000 claims abstract description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 3
- 230000008693 nausea Effects 0.000 claims abstract description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 49
- 150000002923 oximes Chemical class 0.000 claims description 49
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 49
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 48
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 19
- -1 N-pyridyl Chemical group 0.000 claims description 17
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 208000004296 neuralgia Diseases 0.000 claims description 11
- 208000021722 neuropathic pain Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- FROPPAHABGJTLA-UHFFFAOYSA-N (2-fluorophenyl) n-[6-[4,5-bis(4-fluorophenyl)-2-methylimidazol-1-yl]hexyl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 FROPPAHABGJTLA-UHFFFAOYSA-N 0.000 claims description 7
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 claims description 7
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 claims description 7
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 claims description 7
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 7
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 claims description 7
- FTFMPYWXZDLNAM-UHFFFAOYSA-N (2,6-difluorophenyl) n-[6-[4,5-bis(4-fluorophenyl)-2-methylimidazol-1-yl]hexyl]carbamate Chemical compound FC=1C=CC=C(F)C=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 FTFMPYWXZDLNAM-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 208000005298 acute pain Diseases 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 15
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 claims 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 claims 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 1
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 abstract description 16
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 abstract description 15
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000004949 mass spectrometry Methods 0.000 description 92
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 66
- 238000004128 high performance liquid chromatography Methods 0.000 description 62
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 47
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 238000005160 1H NMR spectroscopy Methods 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 31
- 239000000543 intermediate Substances 0.000 description 31
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 229910001868 water Inorganic materials 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 239000007858 starting material Substances 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 238000003818 flash chromatography Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 239000002621 endocannabinoid Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 101150041968 CDC13 gene Proteins 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 7
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 7
- 229930003827 cannabinoid Natural products 0.000 description 7
- 239000003557 cannabinoid Substances 0.000 description 7
- 229910052681 coesite Inorganic materials 0.000 description 7
- 229910052906 cristobalite Inorganic materials 0.000 description 7
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 7
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 229910052682 stishovite Inorganic materials 0.000 description 7
- 229910052905 tridymite Inorganic materials 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 208000004454 Hyperalgesia Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 4
- 108050007331 Cannabinoid receptor Proteins 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 208000035154 Hyperesthesia Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229940065144 cannabinoids Drugs 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229960005181 morphine Drugs 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WBDSXISQIHMTGL-UHFFFAOYSA-N 2-methyl-4,5-diphenyl-1h-imidazole Chemical compound N1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 WBDSXISQIHMTGL-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 3
- LHAHTHILLRCRBM-UHFFFAOYSA-N (2-fluorophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 LHAHTHILLRCRBM-UHFFFAOYSA-N 0.000 description 2
- YCHYFHOSGQABSW-RTBURBONSA-N (6ar,10ar)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid Chemical compound C1C(C(O)=O)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 YCHYFHOSGQABSW-RTBURBONSA-N 0.000 description 2
- WAWFIZWARJFZNB-UHFFFAOYSA-N 1-(3-bromopropyl)-2-methyl-4,5-diphenylimidazole Chemical compound BrCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 WAWFIZWARJFZNB-UHFFFAOYSA-N 0.000 description 2
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 2
- PLWROONZUDKYKG-DOFZRALJSA-N AACOCF3 Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)C(F)(F)F PLWROONZUDKYKG-DOFZRALJSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- YWDYYCUYUHBNGL-UHFFFAOYSA-N benzyl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 YWDYYCUYUHBNGL-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FGYDHYCFHBSNPE-UHFFFAOYSA-N diethyl phenylmalonate Chemical compound CCOC(=O)C(C(=O)OCC)C1=CC=CC=C1 FGYDHYCFHBSNPE-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- UHTNRRRVPYSFKW-UHFFFAOYSA-N ethyl 2-ethyl-7-(2-methyl-4,5-diphenylimidazol-1-yl)heptanoate Chemical compound CCOC(=O)C(CC)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UHTNRRRVPYSFKW-UHFFFAOYSA-N 0.000 description 2
- KADOCUYCTLJXRV-UHFFFAOYSA-N ethyl 7-(2-methyl-4,5-diphenylimidazol-1-yl)heptanoate Chemical compound CCOC(=O)CCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 KADOCUYCTLJXRV-UHFFFAOYSA-N 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- ZFCUKLAHWGJHDA-UHFFFAOYSA-N (2,4-difluorophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=C(F)C=C(F)C=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 ZFCUKLAHWGJHDA-UHFFFAOYSA-N 0.000 description 1
- AYBJAAXONTZTRT-UHFFFAOYSA-N (2,6-dimethoxyphenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound COC1=CC=CC(OC)=C1OC(=O)NCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C AYBJAAXONTZTRT-UHFFFAOYSA-N 0.000 description 1
- TXTYAAMKKBDEHL-UHFFFAOYSA-N (2,6-dimethoxyphenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound COC1=CC=CC(OC)=C1OC(=O)NCCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C TXTYAAMKKBDEHL-UHFFFAOYSA-N 0.000 description 1
- VHHYCPSXRJPUPU-UHFFFAOYSA-N (2,6-dimethoxyphenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound COC1=CC=CC(OC)=C1OC(=O)NCCCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C VHHYCPSXRJPUPU-UHFFFAOYSA-N 0.000 description 1
- HMJCRVRGZFQOMD-UHFFFAOYSA-N (2-fluorophenyl) n-[2-methyl-8-(2-methyl-4,5-diphenylimidazol-1-yl)octan-3-yl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NC(C(C)C)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HMJCRVRGZFQOMD-UHFFFAOYSA-N 0.000 description 1
- HVBXMFCCTUBMJH-UHFFFAOYSA-N (2-fluorophenyl) n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C(=CC=CC=2)F)C=CC=1OCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HVBXMFCCTUBMJH-UHFFFAOYSA-N 0.000 description 1
- BWPRPBUIQPVVFD-UHFFFAOYSA-N (2-fluorophenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 BWPRPBUIQPVVFD-UHFFFAOYSA-N 0.000 description 1
- LVGPJSBRMDHIRR-UHFFFAOYSA-N (2-fluorophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)-1-phenylhexyl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NC(C=1C=CC=CC=1)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 LVGPJSBRMDHIRR-UHFFFAOYSA-N 0.000 description 1
- LXGNTFODLNMYKQ-UHFFFAOYSA-N (2-fluorophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptan-2-yl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NC(C)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 LXGNTFODLNMYKQ-UHFFFAOYSA-N 0.000 description 1
- KVVFDLOMTIYNNM-UHFFFAOYSA-N (2-fluorophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 KVVFDLOMTIYNNM-UHFFFAOYSA-N 0.000 description 1
- MLFASIRABYZUIU-UHFFFAOYSA-N (2-methoxyphenyl) n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound COC1=CC=CC=C1OC(=O)NC(C=C1)=CC=C1OCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C MLFASIRABYZUIU-UHFFFAOYSA-N 0.000 description 1
- WUTDHSLCSCRJJE-UHFFFAOYSA-N (2-methoxyphenyl) n-[4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]phenyl]carbamate Chemical compound COC1=CC=CC=C1OC(=O)NC(C=C1)=CC=C1OCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C WUTDHSLCSCRJJE-UHFFFAOYSA-N 0.000 description 1
- FZGDFPYGTTVJHF-UHFFFAOYSA-N (2-methoxyphenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound COC1=CC=CC=C1OC(=O)NCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C FZGDFPYGTTVJHF-UHFFFAOYSA-N 0.000 description 1
- SDPQMYWYNNWTLU-UHFFFAOYSA-N (2-methoxyphenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound COC1=CC=CC=C1OC(=O)NCCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C SDPQMYWYNNWTLU-UHFFFAOYSA-N 0.000 description 1
- IUNZJOWJONPLGO-UHFFFAOYSA-N (2-methoxyphenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound COC1=CC=CC=C1OC(=O)NCCCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C IUNZJOWJONPLGO-UHFFFAOYSA-N 0.000 description 1
- UXFHDVNGNFTBIX-UHFFFAOYSA-N (2-methylphenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C=1C=CC=C(C)C=1OC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UXFHDVNGNFTBIX-UHFFFAOYSA-N 0.000 description 1
- IBVGJCKUNHQTJG-UHFFFAOYSA-N (2-methylphenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=CC=C(C)C=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 IBVGJCKUNHQTJG-UHFFFAOYSA-N 0.000 description 1
- NBASSYYNACEAGJ-UHFFFAOYSA-N (2-methylphenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=CC=C(C)C=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 NBASSYYNACEAGJ-UHFFFAOYSA-N 0.000 description 1
- DNURSCPDSPXAJU-UHFFFAOYSA-N (3,4-difluorophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=C(F)C(F)=CC=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 DNURSCPDSPXAJU-UHFFFAOYSA-N 0.000 description 1
- RFLKXRLXXACOCO-UHFFFAOYSA-N (3-chlorophenyl) n-[4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=C(Cl)C=CC=2)C=CC=1OCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 RFLKXRLXXACOCO-UHFFFAOYSA-N 0.000 description 1
- WOLFTIJTUYIRFQ-UHFFFAOYSA-N (4-chlorophenyl) n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=CC(Cl)=CC=2)C=CC=1OCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 WOLFTIJTUYIRFQ-UHFFFAOYSA-N 0.000 description 1
- QLVDMDDQLWVPLM-UHFFFAOYSA-N (4-chlorophenyl) n-[4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=CC(Cl)=CC=2)C=CC=1OCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 QLVDMDDQLWVPLM-UHFFFAOYSA-N 0.000 description 1
- XJAKUYMMKREWNM-UHFFFAOYSA-N (4-chlorophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=C(Cl)C=CC=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 XJAKUYMMKREWNM-UHFFFAOYSA-N 0.000 description 1
- WJLTUBGHNUKNRQ-UHFFFAOYSA-N (4-chlorophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=C(Cl)C=CC=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 WJLTUBGHNUKNRQ-UHFFFAOYSA-N 0.000 description 1
- JQCVZSZSAVHKDK-UHFFFAOYSA-N (4-cyanophenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C=1C=C(C#N)C=CC=1OC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JQCVZSZSAVHKDK-UHFFFAOYSA-N 0.000 description 1
- WCFPXERLDSROKC-UHFFFAOYSA-N (4-cyanophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=C(C#N)C=CC=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 WCFPXERLDSROKC-UHFFFAOYSA-N 0.000 description 1
- SHTWNZPEBIGSSW-UHFFFAOYSA-N (4-fluorophenyl) n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=CC(F)=CC=2)C=CC=1OCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 SHTWNZPEBIGSSW-UHFFFAOYSA-N 0.000 description 1
- CSFBUGVVQNTZGS-UHFFFAOYSA-N (4-fluorophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=C(F)C=CC=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CSFBUGVVQNTZGS-UHFFFAOYSA-N 0.000 description 1
- YEYYSMBWLXKXSJ-UHFFFAOYSA-N (4-fluorophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=C(F)C=CC=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 YEYYSMBWLXKXSJ-UHFFFAOYSA-N 0.000 description 1
- DBTOBDWFVHSNGN-UHFFFAOYSA-N (4-methoxyphenyl) n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1OC(=O)NC(C=C1)=CC=C1OCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C DBTOBDWFVHSNGN-UHFFFAOYSA-N 0.000 description 1
- CTCPSLZBROEIJK-UHFFFAOYSA-N (4-methoxyphenyl) n-[4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1OC(=O)NC(C=C1)=CC=C1OCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C CTCPSLZBROEIJK-UHFFFAOYSA-N 0.000 description 1
- ZCXQKBFXBDHCMV-UHFFFAOYSA-N (4-methoxyphenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C1=CC(OC)=CC=C1OC(=O)NCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C ZCXQKBFXBDHCMV-UHFFFAOYSA-N 0.000 description 1
- ABKJPGCDYPXWKQ-UHFFFAOYSA-N (4-methoxyphenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C1=CC(OC)=CC=C1OC(=O)NCCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C ABKJPGCDYPXWKQ-UHFFFAOYSA-N 0.000 description 1
- FMVHVRYFQIXOAF-CGRWFSSPSA-N (7e,10e,13e,16e)-n-(2-hydroxyethyl)docosa-7,10,13,16-tetraenamide Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(=O)NCCO FMVHVRYFQIXOAF-CGRWFSSPSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 1
- DCQWOKVSKCZSCU-UHFFFAOYSA-N 1-(6-bromohexyl)-2-methyl-4,5-diphenylimidazole Chemical compound BrCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 DCQWOKVSKCZSCU-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- JFGCBMQXGWFESU-UHFFFAOYSA-N 2-ethyl-4,5-diphenyl-1h-imidazole Chemical compound N1C(CC)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JFGCBMQXGWFESU-UHFFFAOYSA-N 0.000 description 1
- BNPWVUJOPCGHIK-UHFFFAOYSA-N 3,4-difluorophenol Chemical compound OC1=CC=C(F)C(F)=C1 BNPWVUJOPCGHIK-UHFFFAOYSA-N 0.000 description 1
- DRBDPIAOSYZKQD-UHFFFAOYSA-N 4,5-bis(4-fluorophenyl)-2-methyl-1h-imidazole Chemical compound N1C(C)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 DRBDPIAOSYZKQD-UHFFFAOYSA-N 0.000 description 1
- WMAATRDUOAZYRH-UHFFFAOYSA-N 4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1OCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 WMAATRDUOAZYRH-UHFFFAOYSA-N 0.000 description 1
- YCDQLNHZDLUPDC-UHFFFAOYSA-N 4-chlorobutyl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound ClCCCCOC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 YCDQLNHZDLUPDC-UHFFFAOYSA-N 0.000 description 1
- NVTHULYBHMPHQJ-UHFFFAOYSA-N 6-(2-methyl-4,5-diphenylimidazol-1-yl)hexanoic acid Chemical compound OC(=O)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 NVTHULYBHMPHQJ-UHFFFAOYSA-N 0.000 description 1
- JRHDWMZXBJHQPC-UHFFFAOYSA-N 7-(2-methyl-4,5-diphenylimidazol-1-yl)-2-phenylheptanoic acid Chemical compound C=1C=CC=CC=1C(C(O)=O)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JRHDWMZXBJHQPC-UHFFFAOYSA-N 0.000 description 1
- QYBNPFICEBDYAQ-UHFFFAOYSA-N 7-(2-methyl-4,5-diphenylimidazol-1-yl)-2-propan-2-ylheptanoic acid Chemical compound CC(C)C(C(O)=O)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 QYBNPFICEBDYAQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- YLEARPUNMCCKMP-DOFZRALJSA-N N-arachidonoylglycine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCC(O)=O YLEARPUNMCCKMP-DOFZRALJSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 230000003063 anti-neuropathic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical compound C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 102220347004 c.89G>A Human genes 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- OAYRYNVEFFWSHK-UHFFFAOYSA-N carsalam Chemical compound C1=CC=C2OC(=O)NC(=O)C2=C1 OAYRYNVEFFWSHK-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- JCUFQSXXINWVIU-UHFFFAOYSA-N cyclohexyl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C1CCCCC1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JCUFQSXXINWVIU-UHFFFAOYSA-N 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- UZHAAVVGHAYURO-UHFFFAOYSA-N diethyl 2-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]-2-phenylpropanedioate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)(C(=O)OCC)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UZHAAVVGHAYURO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- JIZHOPJSMAYQIB-UHFFFAOYSA-N ethyl 2-methyl-7-(2-methyl-4,5-diphenylimidazol-1-yl)heptanoate Chemical compound CCOC(=O)C(C)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JIZHOPJSMAYQIB-UHFFFAOYSA-N 0.000 description 1
- PQXMPJGYWQAWPW-UHFFFAOYSA-N ethyl 4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C PQXMPJGYWQAWPW-UHFFFAOYSA-N 0.000 description 1
- FERMEWWTTUTDDV-UHFFFAOYSA-N ethyl 6-(2-methyl-4,5-diphenylimidazol-1-yl)hexanoate Chemical compound CCOC(=O)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 FERMEWWTTUTDDV-UHFFFAOYSA-N 0.000 description 1
- ALGSAAUKYXPCAA-UHFFFAOYSA-N ethyl 7-(2-methyl-4,5-diphenylimidazol-1-yl)-2-propan-2-ylheptanoate Chemical compound CCOC(=O)C(C(C)C)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 ALGSAAUKYXPCAA-UHFFFAOYSA-N 0.000 description 1
- BZNKOJZOSNRABX-UHFFFAOYSA-N ethyl 7-[4,5-bis(4-fluorophenyl)-2-methylimidazol-1-yl]heptanoate Chemical compound CCOC(=O)CCCCCCN1C(C)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 BZNKOJZOSNRABX-UHFFFAOYSA-N 0.000 description 1
- OOBFNDGMAGSNKA-UHFFFAOYSA-N ethyl 7-bromoheptanoate Chemical compound CCOC(=O)CCCCCCBr OOBFNDGMAGSNKA-UHFFFAOYSA-N 0.000 description 1
- MVTNIYDFOXZYNZ-UHFFFAOYSA-N ethyl 8-(2-methyl-4,5-diphenylimidazol-1-yl)octanoate Chemical compound CCOC(=O)CCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 MVTNIYDFOXZYNZ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- WIHGSFJBAYXSNS-UHFFFAOYSA-N ethyl n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1OCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C WIHGSFJBAYXSNS-UHFFFAOYSA-N 0.000 description 1
- VZSXUVQCPYUMAW-UHFFFAOYSA-N ethyl n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound CCOC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 VZSXUVQCPYUMAW-UHFFFAOYSA-N 0.000 description 1
- GSVJWQNGCOHAMM-UHFFFAOYSA-N ethyl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound CCOC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 GSVJWQNGCOHAMM-UHFFFAOYSA-N 0.000 description 1
- VJHMAYPKFOEEMF-UHFFFAOYSA-N ethyl n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound CCOC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 VJHMAYPKFOEEMF-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- CRYHRFPPPYGXLU-UHFFFAOYSA-N methyl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound COC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CRYHRFPPPYGXLU-UHFFFAOYSA-N 0.000 description 1
- OFSWZLPOOKDXDP-UHFFFAOYSA-N methyl n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound COC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFSWZLPOOKDXDP-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 229950007031 palmidrol Drugs 0.000 description 1
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- RNYLSGGTAIRFDR-UHFFFAOYSA-N phenyl n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=CC=CC=2)C=CC=1OCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 RNYLSGGTAIRFDR-UHFFFAOYSA-N 0.000 description 1
- VNIZFYRBACXAQP-UHFFFAOYSA-N phenyl n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C=1C=CC=CC=1OC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 VNIZFYRBACXAQP-UHFFFAOYSA-N 0.000 description 1
- UWKODOYNVJUKMA-UHFFFAOYSA-N phenyl n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=CC=CC=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UWKODOYNVJUKMA-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- DWNVRDYRAQCINB-UHFFFAOYSA-N propan-2-yl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound CC(C)OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 DWNVRDYRAQCINB-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- VLTNNAFYFSVVGS-UHFFFAOYSA-N tert-butyl n-[6-(2-ethyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCN1C(CC)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 VLTNNAFYFSVVGS-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28682701P | 2001-04-27 | 2001-04-27 | |
| US60/286,827 | 2001-04-27 | ||
| PCT/US2002/012853 WO2002087569A1 (en) | 2001-04-27 | 2002-04-23 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2445294A1 true CA2445294A1 (en) | 2002-11-07 |
Family
ID=23100337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002445294A Abandoned CA2445294A1 (en) | 2001-04-27 | 2002-04-23 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6562846B2 (https=) |
| EP (1) | EP1389107A4 (https=) |
| JP (1) | JP2004532229A (https=) |
| CA (1) | CA2445294A1 (https=) |
| IL (1) | IL158300A0 (https=) |
| MX (1) | MXPA03009850A (https=) |
| WO (1) | WO2002087569A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002311784B2 (en) * | 2001-03-29 | 2007-11-22 | Michael Davis | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| US6949574B2 (en) * | 2002-02-08 | 2005-09-27 | Bristol-Myers Squibb Company | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| EP1558591B1 (en) | 2002-10-07 | 2014-05-07 | The Regents of The University of California | Modulation of anxiety through blockade of anandamide hydrolysis |
| FR2850377B1 (fr) * | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866884B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
| FR2866886B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
| FR2866885B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
| US20080103209A1 (en) * | 2004-04-23 | 2008-05-01 | The Regents Of The University Of California | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists |
| US7351724B2 (en) | 2004-10-15 | 2008-04-01 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
| US20060084659A1 (en) * | 2004-10-19 | 2006-04-20 | Michael Davis | Augmentation of psychotherapy with cannabinoid reuptake inhibitors |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| AR055831A1 (es) | 2004-12-30 | 2007-09-12 | Janssen Pharmaceutica Nv | Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos |
| ES2357129T3 (es) * | 2005-04-13 | 2011-04-19 | Neuraxon Inc. | Compuestos indólicos sustituidos que tienen actividad inhibidora de nos. |
| WO2006116773A2 (en) * | 2005-04-28 | 2006-11-02 | The Regents Of The University Of California | Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders |
| JP2009527483A (ja) | 2006-02-17 | 2009-07-30 | ザ・スクリプス・リサーチ・インステイチユート | 脂肪酸アミドヒドロラーゼの調節因子としてのオキサゾールケトン |
| KR100753240B1 (ko) | 2006-03-10 | 2007-08-30 | 한국지질자원연구원 | 합금 나노분말의 제조방법 |
| CA2702468A1 (en) * | 2007-10-12 | 2009-04-23 | University Of Connecticut | Therapeutic applications of fatty acid amide hydrolase inhibitors |
| EP2062578A1 (en) * | 2007-11-12 | 2009-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel use of chemical compounds for the treatment of AIDS |
| KR20100103799A (ko) | 2007-11-16 | 2010-09-28 | 네우렉슨 인코포레이티드 | 내장통을 치료하기 위한 인돌 화합물 및 방법 |
| CA2714743C (en) | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| US8207226B1 (en) | 2008-06-03 | 2012-06-26 | Alcon Research, Ltd. | Use of FAAH antagonists for treating dry eye and ocular pain |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| US8598356B2 (en) | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| ES2626246T3 (es) | 2009-09-09 | 2017-07-24 | Sumitomo Dainippon Pharma Co., Ltd. | Derivado de 8-oxodihidropurina |
| US20120225097A1 (en) | 2009-11-12 | 2012-09-06 | Hawryluk Natalie A | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| DE102012018115A1 (de) | 2012-09-13 | 2014-03-13 | Matthias Lehr | Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase |
| EP2931291B1 (en) | 2012-12-11 | 2021-10-20 | The McLean Hospital Corporation | Xenon treatment as an adjunct to psychotherapy for psychiatric disorders |
| DE102013016573A1 (de) | 2013-10-04 | 2015-04-09 | Matthias Lehr | 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung |
| US10414721B1 (en) | 2018-06-04 | 2019-09-17 | University Of Bern | Inhibitor of endocannabinoid cellular reuptake |
| CN111269083B (zh) * | 2020-02-24 | 2023-08-25 | 珠海市柏瑞医药科技有限公司 | 一种格尔伯特酸的合成方法 |
| US11999703B1 (en) | 2023-10-25 | 2024-06-04 | King Faisal University | 5-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid as an antimicrobial compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT91878B (pt) * | 1988-10-03 | 1995-05-31 | Glaxo Group Ltd | Processo para a preparacao de derivados do imidazole com propriedades hipocolesterolemicas e hipolipidemicas |
| KR100291112B1 (ko) * | 1992-02-11 | 2001-09-17 | 더 존스 홉킨스 유니버시티 | 코엔자임에이-독립성트랜스아실라제및혈소판활성화인자억제제 |
| US5700826A (en) * | 1995-06-07 | 1997-12-23 | Ontogen Corporation | 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance |
-
2002
- 2002-04-23 MX MXPA03009850A patent/MXPA03009850A/es active IP Right Grant
- 2002-04-23 US US10/128,480 patent/US6562846B2/en not_active Ceased
- 2002-04-23 JP JP2002584915A patent/JP2004532229A/ja active Pending
- 2002-04-23 WO PCT/US2002/012853 patent/WO2002087569A1/en not_active Ceased
- 2002-04-23 CA CA002445294A patent/CA2445294A1/en not_active Abandoned
- 2002-04-23 IL IL15830002A patent/IL158300A0/xx unknown
- 2002-04-23 EP EP02728952A patent/EP1389107A4/en not_active Withdrawn
-
2004
- 2004-07-01 US US10/883,195 patent/USRE39634E1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004532229A (ja) | 2004-10-21 |
| US6562846B2 (en) | 2003-05-13 |
| USRE39634E1 (en) | 2007-05-15 |
| US20020188009A1 (en) | 2002-12-12 |
| MXPA03009850A (es) | 2004-02-12 |
| IL158300A0 (en) | 2004-05-12 |
| WO2002087569A1 (en) | 2002-11-07 |
| EP1389107A1 (en) | 2004-02-18 |
| EP1389107A4 (en) | 2005-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2445294A1 (en) | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | |
| US5990126A (en) | Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof | |
| US6906080B1 (en) | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | |
| CN103189337A (zh) | 氨基二氢化茚衍生物、包含所述氨基二氢化茚衍生物的药物组合物及其在治疗中的用途 | |
| RU2248349C2 (ru) | Производные эфиров карбаминовой кислоты, их получение (варианты) и их применение в качестве лигандов метаботропных глутаматных рецепторов | |
| CN103237788A (zh) | 苯烷基胺衍生物、包含所述苯烷基胺衍生物的药物组合物及其在治疗中的用途 | |
| CN104245669A (zh) | 异吲哚啉衍生物、含有其的药物组合物及其在治疗中的用途 | |
| JP2002540155A (ja) | アリール置換ピラゾール、イミダゾール、オキサゾール、チアゾールおよびピロール、ならびにそれらの使用 | |
| JP2010513482A (ja) | アルドステロンシンターゼ阻害剤としてのイミダゾール類 | |
| CN101277934A (zh) | 使代谢型谷氨酸-受体-增效的异吲哚酮 | |
| EP0979228A1 (en) | Novel cannabinoid receptor agonists | |
| TWI385158B (zh) | １ｈ-喹唑啉-２，４-二酮 | |
| AU2004246983A1 (en) | New azetidine compounds | |
| Ksander et al. | Diaminoindanes as microsomal triglyceride transfer protein inhibitors | |
| US6100265A (en) | Thiopyran derivatives | |
| JP4098523B2 (ja) | Ｃｎｓ障害に対するカルボニルアミノ誘導体の使用 | |
| TW200846328A (en) | GlyT1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders | |
| AU2002258973A1 (en) | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | |
| SK1792000A3 (en) | 1,3-DIOXOLO(4,5-H)(2,3)BENZODIAZEPINE DERIVATIVES, PROCESS FORì (54) THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CO | |
| US6803381B1 (en) | Carbamic acid derivatives | |
| JP3930081B2 (ja) | ２−ウレイド−ベンズアミド誘導体 | |
| KR100753905B1 (ko) | Ｎ-치환된-1ｈ-퀴놀린-2,4-디온 화합물, 이의 제조 방법 및이를 포함하는 약학적 조성물 | |
| CN101747327A (zh) | 芳酰胺基噻唑类衍生物及其制备方法和用途 | |
| MXPA00001487A (en) | 1,3-dioxolo/4,5-h//2,3/benzodiazepine derivatives as ampa/kainate receptor inhibitors | |
| HK1088004B (en) | 3-heterocyclyl-azetidine compounds useful as nk1/nk2 receptors antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |